Abstract
SummarySTW 5 (Iberogast®; Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) contains nine plant extracts and possesses well-documented overall efficacy in functional gastrointestinal disorders (FGID). Little is known about the onset of symptom relief. Twenty-nine centers in Germany recruited 272 patients with established FGID. These patients were treated with STW 5 for approximately 3 weeks in this noninterventional study. Patients assessed the severity of their gastrointestinal complaints before and at defined times after the intake of STW 5 (10 cm visual analogue scale; VAS). Fifteen minutes after the first dose, the severity of gastrointestinal complaints had decreased by 1.4 cm (mean; initial mean: 5.2 of 10 cm). After 1 h, more than 90% of the maximum effect of 3.2 cm on the 10 cm VAS had been reached. Most patients with symptoms experienced a marked improvement within 5, 15 or 30 min of taking STW 5. Absolute improvements were larger in patients with more pronounced baseline complaints. Subgroups with upper (80% of the study population) and lower FGID (20%) did not present major differences. Neither did subgroups by age and duration of complaints. Treatment with STW 5 resulted in rapid improvement of symptoms.
Highlights
Functional gastrointestinal disorders (FGID) like functional dyspepsia or irritable bowel syndrome are frequent reasons for patient visits to doctors
The prevalence of FGIDs in Western countries ranges from 10% to more than 20% [1,2,3]
This noninterventional study confirmed that STW 5 improved symptoms of upper and lower functional gastrointestinal disorders (FGIDs)
Summary
Functional gastrointestinal disorders (FGID) like functional dyspepsia or irritable bowel syndrome are frequent reasons for patient visits to doctors. Depending on their definition, the prevalence of FGIDs in Western countries ranges from 10% to more than 20% [1,2,3]. The prevalence of FGIDs in Western countries ranges from 10% to more than 20% [1,2,3] In these patients, diagnostic work-up in the clinical setting does not reveal structural or biochemical abnormalities that can explain the respective symptoms. This study focused on functional and motility related disorders, which are allocated to the gastroduodenal and bowel (intestinal) domain (categories B and C)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
